Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of orelabrutinib in adults with systemic lupus erythematosus
CTR20260496Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Orelabrutinib with Placebo (2 arms). Primary endpoint: SLE Responder Index-4 response rate. Started Apr 2026; status: active.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20260496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260496.